A South Carolina overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
34.6% of South Carolina adults have obesity, according to the CDC's 2024 BRFSS prevalence estimates 1. That ties Missouri for the 21st-highest rate among the 50 states plus D.C. — squarely mid-pack nationally, and lower than every one of South Carolina's Deep South neighbors: Alabama sits at 38.9% 1, Louisiana at 39.2% 1, and Mississippi at 40.4% 1. The state's own rate has hovered in a narrow band for years — 36.1% in 2021, 35.0% in 2022, 36.0% in 2023, and 34.6% in 2024 1 — and because BRFSS is a telephone survey with a published margin of error, we're reporting the latest number, not declaring a downward trend from one year's dip.
The number that actually changed course in South Carolina this year is not the prevalence figure. It is what Healthy Connections Medicaid will pay for — and it moved toward less coverage, not more, at the start of 2026.
No. Healthy Connections Medicaid's current Pharmacy Services Provider Manual lists "weight control products" as a non-covered service "regardless of circumstance," with no GLP-1 exception written anywhere in the document 3.
That's a change, not a constant. The manual version in force through most of 2025 read differently: it excluded weight-control products "except for GLP-1 receptor agonists as listed on the single preferred drug list," and it carried a standalone prior-authorization pathway — "GLP-1 Receptor Agonists for weight management: Refer to the single preferred drug list for a listing of covered drugs (PA required)" 5. Both provisions were deliberately deleted from the manual effective January 1, 2026; DHHS's own Change Control Record logs the edits by name, "Remove GLP1 language for weight loss" and "Remove GLP1 receptor Agonists language" 4. No revision since — through the manual's July 1, 2026 update — has restored either one 3.
The state's Single Preferred Drug List, effective August 1, 2026, confirms the door is shut rather than merely narrowed. In the "GLP-1/GIP Agonists, Injectable" class, only the diabetes-indicated brands appear: Ozempic, Trulicity, and Victoza are preferred; Mounjaro, Soliqua, Xultophy, and generic liraglutide or exenatide are non-preferred and require documented trial-and-failure of every preferred drug first 6. Wegovy, Zepbound, and Saxenda — the three brands actually indicated for obesity — do not appear anywhere on the 25-page list 6. This isn't a fee-for-service quirk either: the sPDL explicitly governs "All Managed Care plans and traditional Fee For Service," so the exclusion applies the same way whether a member is enrolled in FFS or any Healthy Connections MCO 6.
Net effect: a South Carolina Medicaid card gets a member Ozempic, Trulicity, or Victoza only with a type 2 diabetes diagnosis, and only after trying every preferred option first. It does not get a GLP-1 approved for obesity, for any member, under any circumstance, as of this policy update. Commercial coverage is a separate question the state doesn't decide — it depends on what your employer's plan elects — so the practical next step for a Healthy Connections member is checking whether a diabetes diagnosis and the sPDL's step-therapy requirements apply to you, not appealing a weight-only denial the manual no longer carries any exception for.
Nothing about our price is South Carolinian.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
A patient in Charleston pays what a patient anywhere else in the state, or the country, pays. In a state where Medicaid just finished closing its only obesity pathway, we'd rather publish the one number that applies to everyone than run a rate that moves with what a market recently lost access to.
We have not yet independently verified South Carolina's specific telehealth-prescribing statute for this page, so we are not citing one until it has been checked directly against the primary source. What we can point to today is the South Carolina Board of Medical Examiners, the licensing authority for the physicians who would treat a South Carolina patient, and the South Carolina Board of Pharmacy's authority over any compounded medication filled in-state 8.
Separately, whatever a licensed South Carolina provider prescribes, a compounded version of a GLP-1 medication is still governed at the federal level by FDA's Section 503A framework, which — since FDA declared the tirzepatide and semaglutide shortages resolved in December 2024 and February 2025 — generally limits a compounding pharmacy to preparing a copy of an FDA-approved drug only for an individual patient whose prescriber documents a clinically significant difference. That federal baseline applies in South Carolina the same as everywhere else. Whether South Carolina's Board of Pharmacy has layered any additional state-specific restriction on top of it, the way some other states' boards have, is not yet confirmed; until it is, this page does not assert one either way.
Astra serves patients in all 50 states, South Carolina included: our provider group holds South Carolina licensure and our partner pharmacies are licensed to dispense into the state, so a resident of the Upstate, the Pee Dee, or the Lowcountry can complete an intake and receive medication at a South Carolina address without a clinic visit.
South Carolina also added roughly 91,000 residents in 2024 alone — 5,387,830 to 5,478,831, one of the largest single-year population gains of any state — driven overwhelmingly by domestic migration (68,043 net movers from other states, versus 23,234 net international migrants) 2. A lot of that growth is landing outside the state's three biggest metros, in counties whose clinical infrastructure hasn't necessarily kept pace, which is exactly the kind of access gap telehealth is built to close.
Astra treats patients in South Carolina through state-licensed physicians.
Charleston's city page — county-level obesity data, local clinic pricing, and the specialist-access gap — is in progress and will list here automatically once its record publishes, under the same sourcing rules as this page.
No — not for weight loss, and not since January 1, 2026. Healthy Connections Medicaid's Pharmacy Services Provider Manual lists weight control products as non-covered "regardless of circumstance," and the standalone GLP-1 prior-authorization pathway that used to exist for weight management was deliberately removed from the manual effective January 1, 2026. The state's Single Preferred Drug List, effective August 1, 2026, lists only diabetes-indicated brands — Ozempic, Trulicity, and Victoza — in the GLP-1/GIP class; Wegovy, Zepbound, and Saxenda do not appear on it at all.
No, and that's deliberate. Astra charges one price in every state it serves, published once in the cost section above. There's no South Carolina price list, no regional surcharge, and no local discount — the number that applies in Charleston is the same number that applies everywhere else we serve.
Yes, on a narrower basis. Through most of 2025, the manual excluded weight-control products "except for GLP-1 receptor agonists as listed on the single preferred drug list," with a prior-authorization pathway specifically for weight management. DHHS's own Change Control Record shows both provisions were removed effective January 1, 2026, and no manual revision since — through the July 1, 2026 update — has restored them.
Astra's provider group holds South Carolina licensure to evaluate and treat patients in the state. We have not yet independently verified South Carolina's specific telehealth-prescribing statute or Board of Pharmacy compounding rules for this page — that verification is flagged above as unfinished, so we're not citing a specific rule until it has been checked against the primary source.
Tell your care team your new address before your next refill. Treatment is tied to the state you're located in when you're seen, so a provider licensed in your new state has to take over, and the pharmacy has to be licensed to dispense there. Astra serves all 50 states, so we move the plan across without restarting it.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.